Ballester B, Milara J, Cortijo J (2020) Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation. Oncotarget 32341751

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

T1224-p - MUC1 (human) ▲

Modsite: RyVPPsstDRsPyEK SwissProt Entrez-Gene Orthologous residues MUC1 (human): T1224‑p, MUC1 iso2 (human): T1233‑p, MUC1 iso6 (human): T199‑p, MUC1 iso10 (human): T172‑p, MUC1 (mouse): T599‑p, MUC1 (rat): T43‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma Relevant cell lines - cell types - tissues:  A549 (pulmonary), MRC5 (fibroblast) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes TGF-beta increase pirfenidone TGF-beta inhibit treatment-induced increase Downstream Regulation Effect of modification (function):  intracellular localization Effect of modification (process):  cell growth, induced, transcription, induced Comments:  induces nuclear translocation of the p-SMAD3/MUC1-CT/act-ß-catenin complex

Y1229-p - MUC1 (human) ▲

Modsite: sstDRsPyEKVsAGN SwissProt Entrez-Gene Orthologous residues MUC1 (human): Y1229‑p, MUC1 iso2 (human): Y1238‑p, MUC1 iso6 (human): Y204‑p, MUC1 iso10 (human): Y177‑p, MUC1 (mouse): Y604‑p, MUC1 (rat): Y48‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma Relevant cell lines - cell types - tissues:  A549 (pulmonary), MRC5 (fibroblast) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes TGF-beta increase pirfenidone TGF-beta inhibit treatment-induced increase Downstream Regulation Effect of modification (function):  intracellular localization Effect of modification (process):  cell growth, induced, transcription, induced Comments:  induces nuclear translocation of the p-SMAD3/MUC1-CT/act-ß-catenin complex